Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Day One Biopharmaceuticals (DAWN) Assets Average (2022 - 2025)

Historic Assets Average for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Q3 2025 value amounting to $516.4 million.

  • Day One Biopharmaceuticals' Assets Average rose 315.34% to $516.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $516.4 million, marking a year-over-year increase of 315.34%. This contributed to the annual value of $479.4 million for FY2024, which is 3223.32% up from last year.
  • Latest data reveals that Day One Biopharmaceuticals reported Assets Average of $516.4 million as of Q3 2025, which was up 315.34% from $526.7 million recorded in Q2 2025.
  • Day One Biopharmaceuticals' Assets Average's 5-year high stood at $591.8 million during Q4 2024, with a 5-year trough of $335.9 million in Q2 2022.
  • In the last 4 years, Day One Biopharmaceuticals' Assets Average had a median value of $394.0 million in 2022 and averaged $432.5 million.
  • As far as peak fluctuations go, Day One Biopharmaceuticals' Assets Average tumbled by 610.05% in 2024, and later soared by 5898.04% in 2025.
  • Quarter analysis of 4 years shows Day One Biopharmaceuticals' Assets Average stood at $365.5 million in 2022, then rose by 8.11% to $395.1 million in 2023, then skyrocketed by 49.78% to $591.8 million in 2024, then fell by 12.74% to $516.4 million in 2025.
  • Its Assets Average was $516.4 million in Q3 2025, compared to $526.7 million in Q2 2025 and $558.6 million in Q1 2025.